These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 29337597)

  • 41. Treatment of beta-thalassemia with hydroxyurea (HU)--effects of HU on globin gene expression.
    Huang SZ; Ren ZR; Chen MJ; Xu HP; Zeng YT; Rodgers GP; Zeng FY; Schechter AN
    Sci China B; 1994 Nov; 37(11):1350-9. PubMed ID: 7865126
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pharmacoproteomics Profiling of Plasma From β-Thalassemia Patients in Response to Hydroxyurea Treatment.
    Zohaib M; Ansari SH; Shamsi TS; Zubarev RA; Zarina S
    J Clin Pharmacol; 2019 Jan; 59(1):98-106. PubMed ID: 30152032
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Quantification of HBG mRNA in primary erythroid cultures: prediction of the response to hydroxyurea in sickle cell and beta-thalassemia.
    Pecoraro A; Rigano P; Troia A; Calzolari R; Scazzone C; Maggio A; Steinberg MH; Di Marzo R
    Eur J Haematol; 2014 Jan; 92(1):66-72. PubMed ID: 24112139
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Hydroxyurea Treatment in Transfusion-Dependent β-Thalassemia Patients.
    Bordbar MR; Silavizadeh S; Haghpanah S; Kamfiroozi R; Bardestani M; Karimi M
    Iran Red Crescent Med J; 2014 Jun; 16(6):e18028. PubMed ID: 25068055
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comparative study of hypogonadism in beta-thalassemia intermedia patients with and without hydroxyurea.
    Karimi M; Zekavat OR; Haghpanah S; Javad P; Karamizadeh Z
    Hematology; 2012 Mar; 17(2):122-4. PubMed ID: 22664052
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Hydroxyurea treatment in β-thalassemia patients: to respond or not to respond?
    Banan M
    Ann Hematol; 2013 Mar; 92(3):289-99. PubMed ID: 23318979
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Treatment with hydroxyurea in thalassemia intermedia with paravertebral pseudotumors of extramedullary hematopoiesis.
    Cario H; Wegener M; Debatin KM; Kohne E
    Ann Hematol; 2002 Aug; 81(8):478-82. PubMed ID: 12224008
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The effect of hydroxyurea on the coagulation system in sickle cell anemia and beta-thalassemia intermedia patients: a preliminary study.
    Koc A; Gumruk F; Gurgey A
    Pediatr Hematol Oncol; 2003 Sep; 20(6):429-34. PubMed ID: 14631615
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Fetal haemoglobin augmentation in E/beta(0) thalassaemia: clinical and haematological outcome.
    Singer ST; Kuypers FA; Olivieri NF; Weatherall DJ; Mignacca R; Coates TD; Davies S; Sweeters N; Vichinsky EP;
    Br J Haematol; 2005 Nov; 131(3):378-88. PubMed ID: 16225658
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Adverse effects of hydroxyurea in beta-thalassemia intermedia patients: 10 years' experience.
    Karimi M; Cohan N; Mousavizadeh K; Falahi MJ; Haghpanah S
    Pediatr Hematol Oncol; 2010 Apr; 27(3):205-11. PubMed ID: 20367264
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Preliminary report: hydroxyurea produces significant clinical response in thalassemia intermedia.
    Styles L; Lewis B; Foote D; Cuda L; Vichinsky EP
    Ann N Y Acad Sci; 1998 Jun; 850():461-2. PubMed ID: 9668584
    [No Abstract]   [Full Text] [Related]  

  • 52. Effect of hydroxyurea on the transfusion requirements in patients with severe HbE-beta-thalassaemia: a genotypic and phenotypic study.
    Italia KY; Jijina FF; Merchant R; Panjwani S; Nadkarni AH; Sawant PM; Nair SB; Ghosh K; Colah RB
    J Clin Pathol; 2010 Feb; 63(2):147-50. PubMed ID: 20154037
    [TBL] [Abstract][Full Text] [Related]  

  • 53. KLF10 gene expression is associated with high fetal hemoglobin levels and with response to hydroxyurea treatment in β-hemoglobinopathy patients.
    Borg J; Phylactides M; Bartsakoulia M; Tafrali C; Lederer C; Felice AE; Papachatzopoulou A; Kourakli A; Stavrou EF; Christou S; Hou J; Karkabouna S; Lappa-Manakou C; Ozgur Z; van Ijcken W; von Lindern M; Grosveld FG; Georgitsi M; Kleanthous M; Philipsen S; Patrinos GP
    Pharmacogenomics; 2012 Oct; 13(13):1487-500. PubMed ID: 23057549
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Echocardiographic finding in beta-thalassemia intermedia and major: absence of pulmonary hypertension following hydroxyurea treatment in beta-thalassemia intermedia.
    Karimi M; Borzouee M; Mehrabani A; Cohan N
    Eur J Haematol; 2009 Mar; 82(3):213-8. PubMed ID: 19077048
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A Pragmatic Scoring Tool to Predict Hydroxyurea Response Among β-Thalassemia Major Patients in Pakistan.
    Ansari SH; Hussain Z; Zohaib M; Parveen S; Kaleem B; Qamar H; Adil O; Khan MT; Shamsi TS
    J Pediatr Hematol Oncol; 2022 Jan; 44(1):e77-e83. PubMed ID: 33710118
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The activity of superoxide dismutase in hydroxyurea-treated E beta thalassemia.
    Ajanta H; Chakraborty S; Madhusnata D; Bhattacharya DK; Manisha D
    J Assoc Physicians India; 2002 Aug; 50():1034-5. PubMed ID: 12421025
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Blood transfusion versus hydroxyurea in beta-thalassemia in Iran: a cost-effectiveness study.
    Ravangard R; Mirzaei Z; Keshavarz K; Haghpanah S; Karimi M
    Hematology; 2018 Aug; 23(7):417-422. PubMed ID: 29157136
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Do alpha deletions influence hydroxyurea response in thalassemia intermedia?
    Panigrahi I; Dixit A; Arora S; Kabra M; Mahapatra M; Choudhry VP; Saxena R
    Hematology; 2005 Feb; 10(1):61-3. PubMed ID: 16019448
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Evaluation of the combination therapy of hydroxyurea and thalidomide in β-thalassemia.
    Ansari SH; Ansari I; Wasim M; Sattar A; Khawaja S; Zohaib M; Hussain Z; Adil SO; Ansari AH; Ansari UH; Farooq F; Masqati NU
    Blood Adv; 2022 Dec; 6(24):6162-6168. PubMed ID: 35477175
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Long-term clinical efficacy and safety of thalidomide in patients with transfusion-dependent β-thalassemia: results from Thal-Thalido study.
    Ali Z; Ismail M; Rehman IU; Rani GF; Ali M; Khan MTM
    Sci Rep; 2023 Aug; 13(1):13592. PubMed ID: 37604857
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.